Naohiro Oda

876 total citations
72 papers, 576 citations indexed

About

Naohiro Oda is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Naohiro Oda has authored 72 papers receiving a total of 576 indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Pulmonary and Respiratory Medicine, 26 papers in Oncology and 11 papers in Surgery. Recurrent topics in Naohiro Oda's work include Lung Cancer Treatments and Mutations (13 papers), Cancer Immunotherapy and Biomarkers (13 papers) and Lung Cancer Diagnosis and Treatment (8 papers). Naohiro Oda is often cited by papers focused on Lung Cancer Treatments and Mutations (13 papers), Cancer Immunotherapy and Biomarkers (13 papers) and Lung Cancer Diagnosis and Treatment (8 papers). Naohiro Oda collaborates with scholars based in Japan, United States and Australia. Naohiro Oda's co-authors include Katsuyuki Kiura, Yoshinobu Maeda, Eiki Ichihara, Katsuyuki Hotta, Koji Inoue, Nobuaki Ochi, Daijiro Harada, Naofumi Hara, Shinobu Hosokawa and Nobuaki Miyahara and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Naohiro Oda

70 papers receiving 569 citations

Peers

Countries citing papers authored by Naohiro Oda

Since Specialization

Citations

This map shows the geographic impact of Naohiro Oda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Naohiro Oda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Naohiro Oda more than expected).

Fields of papers citing papers by Naohiro Oda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Naohiro Oda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Naohiro Oda. The network helps show where Naohiro Oda may publish in the future.

Co-authorship network of co-authors of Naohiro Oda

This figure shows the co-authorship network connecting the top 25 collaborators of Naohiro Oda. A scholar is included among the top collaborators of Naohiro Oda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Naohiro Oda. Naohiro Oda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Kidney Injury in Patient with Non-small-cell Lung Cancer Receiving Tepotinib 2024 ·Internal Medicine ·Naohiro Oda, (unknown), (unknown), Takehiko Tokura, Ichiro Takata	0
2	Increased Oxidative Stress and Decreased Citrulline in Blood Associated with Severe Novel Coronavirus Pneumonia in Adult Patients 2024 ·International Journal of Molecular Sciences ·Mitsuru Tsuge, Eiki Ichihara, Kou Hasegawa, Kenichiro Kudo, Yasushi Tanimoto, Kazuhiro Nouso, Naohiro Oda, (unknown), Goro Kimura, (unknown), Ichiro Takata, Toshiharu Mitsuhashi, Akihiko Taniguchi, Kohei Tsukahara, Toshiyuki Aokage, Hideharu Hagiya, Shinichi Toyooka, Hirokazu Tsukahara, Yoshinobu Maeda	1
3	Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non‐small‐cell lung cancer 2024 ·International Journal of Cancer ·Ayako Morita, Eiki Ichihara, Koji Inoue, Keiichi Fujiwara, Toshihide Yokoyama, Daijiro Harada, (unknown), Hirohisa Kano, Naohiro Oda, Tomoki Tamura, Nobuaki Ochi, Haruyuki Kawai, Masaaki Inoue, Naofumi Hara, Nobukazu Fujimoto, (unknown), Isao Oze, Katsuyuki Hotta, Yoshinobu Maeda, Katsuyuki Kiura	14
4	Frequency and Significance of Body Weight Loss During Immunochemotherapy in Patients with Advanced Non-Small Cell Lung Cancer 2024 ·Cancers ·(unknown), Eiki Ichihara, Toshihide Yokoyama, (unknown), Tomoki Tamura, Akiko Satô, Naohiro Oda, Hirohisa Kano, Kayo Nakamura, Haruyuki Kawai, (unknown), (unknown), Nobukazu Fujimoto, (unknown), (unknown), Isao Oze, Katsuyuki Kiura, Yoshinobu Maeda, Katsuyuki Hotta	2
5	Efficacy of immune checkpoint inhibitor monotherapy in elderly patients with non-small-cell lung cancer 2023 ·Respiratory Investigation ·Toshio Kubo, Eiki Ichihara, Daijiro Harada, Koji Inoue, Keiichi Fujiwara, (unknown), Daizo Kishino, Haruyuki Kawai, Nobuaki Ochi, Naohiro Oda, Naofumi Hara, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura	3
6	A randomized controlled trial of teprenone in terms of preventing worsening of COVID-19 infection 2023 ·PLoS ONE ·Eiki Ichihara, Kou Hasegawa, Kenichiro Kudo, Yasushi Tanimoto, Kazuhiro Nouso, Naohiro Oda, (unknown), (unknown), Ichiro Takata, Hideharu Hagiya, Toshiharu Mitsuhashi, Akihiko Taniguchi, Shinichi Toyooka, Kohei Tsukahara, Toshiyuki Aokage, Hirokazu Tsukahara, Katsuyuki Kiura, Yoshinobu Maeda	1
7	Pembrolizumab in advanced NSCLC patients with poor performance status and high PD-L1 expression: OLCSG 1801 2022 ·International Journal of Clinical Oncology ·Shinobu Hosokawa, Eiki Ichihara, Daijiro Harada, Shoichi Kuyama, Koji Inoue, Kenichi Gemba, (unknown), Yuka Kato, Naohiro Oda, Isao Oze, Tomoki Tamura, Toshiyuki Kozuki, (unknown), (unknown), Katsuyuki Hotta, Akihiro Bessho, (unknown), Katsuyuki Kiura	4
8	The Effect of Pleural Effusion on Prognosis in Patients with Non-Small Cell Lung Cancer Undergoing Immunochemotherapy: A Retrospective Observational Study 2022 ·Cancers ·(unknown), Eiki Ichihara, Toshihide Yokoyama, Koji Inoue, Tomoki Tamura, Ken Sato, Naohiro Oda, Hirohisa Kano, Daizo Kishino, Haruyuki Kawai, Masaaki Inoue, Nobuaki Ochi, Nobukazu Fujimoto, (unknown), (unknown), Katsuyuki Hotta, Yoshinobu Maeda, Katsuyuki Kiura	4
9	Interstitial lung disease after receiving the mRNA-based COVID-19 vaccine tozinameran 2022 ·Respiratory Medicine Case Reports ·Naohiro Oda, (unknown), Ichiro Takata, Mikio Kataoka	3
10	The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non–small-cell lung cancer differ based on PD-L1 expression 2021 ·European Journal of Cancer ·Nobuaki Ochi, Eiki Ichihara, Nagio Takigawa, Daijiro Harada, Koji Inoue, Takuo Shibayama, Shinobu Hosokawa, Daizo Kishino, Shingo Harita, Naohiro Oda, Naofumi Hara, Katsuyuki Hotta, Yoshinobu Maeda, Katsuyuki Kiura	43
11	Significance of PD-L1 expression in the cytological samples of non-small cell lung cancer patients treated with immune checkpoint inhibitors 2021 ·Journal of Cancer Research and Clinical Oncology ·Naofumi Hara, Eiki Ichihara, Daijiro Harada, Koji Inoue, Keiichi Fujiwara, Shinobu Hosokawa, Daizo Kishino, Haruyuki Kawai, Nobuaki Ochi, Naohiro Oda, Katsuyuki Hotta, Yoshinobu Maeda, Katsuyuki Kiura	7
12	Successful treatment of critical coronavirus disease 2019 in a patient with lung cancer concomitant with pembrolizumab‐induced arthritis by methylprednisolone, baricitinib, and remdesivir 2021 ·SHILAP Revista de lepidopterología ·Naohiro Oda, (unknown), (unknown), (unknown), (unknown), (unknown), Toshiaki Okada, Ichiro Takata	4
13	Exacerbation of pulmonary cryptococcosis associated with enhancement of Th2 response in the postpartum period 2021 ·Journal of Infection and Chemotherapy ·(unknown), Naohiro Oda, Yuka Gion, (unknown), (unknown), Ichiro Takata, Akihiko Taniguchi, Yasuharu Sato, Nobuaki Miyahara	2
14	Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors 2020 ·Cancer Immunology Immunotherapy ·Eiki Ichihara, Daijiro Harada, Koji Inoue, Takuo Shibayama, Shinobu Hosokawa, Daizo Kishino, Shingo Harita, Nobuaki Ochi, Naohiro Oda, Naofumi Hara, Katsuyuki Hotta, Yoshinobu Maeda, Katsuyuki Kiura	28
15	Utility of immune checkpoint inhibitors in non‐small‐cell lung cancer patients with poor performance status 2020 ·Cancer Science ·Hirohisa Kano, Eiki Ichihara, Daijiro Harada, Koji Inoue, Hiroe Kayatani, Shinobu Hosokawa, Daizo Kishino, Kazuhiko Watanabe, Nobuaki Ochi, Naohiro Oda, Naofumi Hara, Kiichiro Ninomiya, Katsuyuki Hotta, Yoshinobu Maeda, Katsuyuki Kiura	18
16	The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer 2019 ·Lung Cancer ·Eiki Ichihara, Daijiro Harada, Koji Inoue, Ken Sato, Shinobu Hosokawa, Daizo Kishino, Kazuhiko Watanabe, Nobuaki Ochi, Naohiro Oda, Naofumi Hara, Katsuyuki Hotta, Yoshinobu Maeda, Katsuyuki Kiura	74
17	A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403 2018 ·Cancer Chemotherapy and Pharmacology ·Naohiro Oda, (unknown), Kiichiro Ninomiya, Daisuke Minami, Eiki Ichihara, (unknown), Toshihide Yokoyama, (unknown), Kenichi Chikamori, Nagio Takigawa, Nobuaki Ochi, Shingo Harita, Yoshinobu Maeda, Katsuyuki Kiura	20
18	Protective Effects of Bisoprolol against Acute Exacerbation in Moderate-to-Severe Chronic Obstructive Pulmonary Disease. 2017 ·PubMed ·Akihiko Taniguchi, Nobuaki Miyahara, Naohiro Oda, (unknown), Eiki Ichihara, Isao Oze, Yasushi Tanimoto, (unknown), (unknown), Mitsune Tanimoto, Arihiko Kanehiro, Katsuyuki Kiura	4
19	Long-term effects of beta-blocker use on lung function in Japanese patients with chronic obstructive pulmonary disease 2017 ·International Journal of COPD ·Naohiro Oda, Nobuaki Miyahara, (unknown), Yasushi Tanimoto, (unknown), (unknown), Haruyuki Kawai, Akihiko Taniguchi, (unknown), Mitsune Tanimoto, Arihiko Kanehiro, Katsuyuki Kiura	16
20	Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403 2016 ·Clinical Lung Cancer ·Naohiro Oda, Eiki Ichihara, Katsuyuki Hotta, Kiichiro Ninomiya, Takashi Ninomiya, Toshio Kubo, Daisuke Minami, (unknown), Toshihide Yokoyama, Daijiro Harada, Shoichi Kuyama, (unknown), Koji Inoue, Daizo Kishino, Masaaki Inoue, Nagio Takigawa, Takuo Shibayama, Shingo Harita, Mitsune Tanimoto, Katsuyuki Kiura	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact